|Dr. Mitchell H. Gold M.D.||Exec. Chairman & CEO||817.5k||N/A||1968|
|Dr. Stanford Peng||Pres and Head of R&D||758.64k||N/A||1971|
|Mr. Paul Rickey||Sr. VP, CFO, Treasurer & Sec.||551.8k||N/A||1979|
|Dr. Wayne R. Gombotz||Chief Technology Officer||N/A||N/A||1959|
|Mr. Alexander Sharif||Director of Investor Relations & Corp. Devel.||N/A||N/A||N/A|
|Dr. Jan L. Hillson Ph.D., M.D.||Sr. VP of Clinical Devel.||N/A||N/A||1953|
|Dr. Remy Durand Ph.D.||Chief Bus. Officer||N/A||N/A||N/A|
|Dr. Pamela Holland Ph.D.||Sr. VP of Research||N/A||N/A||N/A|
|Dr. Zelanna Goldberg M.D.||Chief Medical Officer||N/A||N/A||N/A|
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Alpine Immune Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.